Anavex Life Sciences Corporation (AVXL)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Anavex Life Sciences Corporation chart...

About the Company

anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.

$M

Total Revenue

28

Employees

$419M

Market Capitalization

-19.55

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $AVXL News

Class Action Filed Against Anavex Life Sciences Corporation (AVXL) Seeking Recovery for Investors - Contact Levi & Korsinsky

12h ago, source:

NEW YORK, NY / ACCESSWIRE / March 18, 2024 / If you suffered a loss on your Anavex Life Sciences Corporation (NASDAQ:AVXL) investment and want to ...

Shareholders that lost money on Anavex Life Sciences Corporation (AVXL) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

18h ago, source: Stockhouse

THE LAWSUIT: A class action securities lawsuit was filed against Anavex Life Sciences Corporation that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud ...

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

14h ago, source:

First patient screened ahead of scheduleTrial to investigate positive, negative, and cognitive domains of schizophreniaANAVEX®3-71’s ...

Anavex Allegedly Hid Clinical Trial Issues Before Stock Drop

4d ago, source:

Anavex Life Sciences Corp. and CEO Christopher Missling concealed from investors that clinical trials had used different ...

Levi & Korsinsky Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline - AVXL

4d ago, source:

NDAQ:AVXL) Levi & Korsinsky Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline - AVXL ...

Anavex Life Sciences Corporation’s (AVXL) Volatility Reaches 5.52%: Don’t Be Comfortable

12d ago, source:

Anavex Life Sciences Corporation (NASDAQ:AVXL) price on Wednesday, March 06, rose 0.80% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $5.02. A look at ...

AVXL Apr 2024 10.000 call

12h ago, source: Yahoo Finance

First patient screened ahead of schedule Trial to investigate positive, negative, and cognitive domains of schizophrenia ANAVEX®3-71’s differentiated dual novel mechanism of action offers the ...

AVXL Mar 2024 5.500 call

3d ago, source: Yahoo Finance

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...

Jefferies, BMO bullish on newly public Metagenomi

on MSN ago, source:

Jefferies and BMO have initiated coverage of newly public Metagenomi (MGX) with bullish ratings, citing the company’s wide array of gene editing tools. Read more here.

Anavex Life Sciences Corp.: Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX3-71 in Schizophrenia

14h ago, source: Finanznachrichten

All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect ...

AVXL Oct 2024 10.000 call

4d ago, source: Yahoo Finance

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...